Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10901427 | PMC |
| http://dx.doi.org/10.14309/crj.0000000000001287 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Portal Vein Arterialization as a Lifesaving Strategy for Hepatic Artery Injury in Robotic Hepatectomy.
Ann Surg Oncol
January 2025
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Article Synopsis
- Robotic vascular resection and reconstruction is complex, and portal vein arterialization (PVA) is an effective alternative when the hepatic artery can't be repaired, enhancing liver oxygen supply and promoting regeneration.
- A case study describes a 52-year-old man with cholangiocarcinoma who underwent robotic left-liver-first surgery, but sustained an artery injury, leading to the use of PVA for successful artery-portal vein anastomosis.
- The surgery lasted 490 minutes with a blood loss of about 300 mL, and although there was a bile leak post-surgery, the patient recovered without experiencing liver failure.
TACE Combined with Portal Vein Tumor Thrombus I Seed Implantation in the Treatment of HCC with Hepatic Arterioportal Shunts.
J Hepatocell Carcinoma
September 2024
Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People's Republic of China.
Background And Objectives: Transarterial chemoembolization (TACE) and I seed implantation are methods used to treat hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), PVTT often associated with arterioportal shunts(APS), there are few reports on the combined use of TACE and I seed implantation for such patients. This study aimed to evaluate the efficacy and safety of TACE combined with PVTT I seed implantation in the treatment of HCC patients with APS.
Methods: Forty-two patients diagnosed with HCC combined with PVTT and APS between January 2020 and December 2021 were included.
Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and PD-1 Inhibitors for Managing Arterioportal Shunt in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Cohort Study.
J Hepatocell Carcinoma
July 2024
Department of Interventional Radiology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, People's Republic of China.
Purpose: This study aimed to assess the effectiveness and safety of combining hepatic arterial infusion chemotherapy (HAIC) with lenvatinib (LEN) and PD-1 inhibitors in treating arterioportal shunt (APS) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT).
Patients And Methods: Conducted retrospectively, the study enrolled 54 HCC patients with APS and PVTT treated with HAIC, LEN, and PD-1 inhibitors at our center between January 2021 and October 2023. APS improvement, APS recanalization, tumor response, PVTT response rate, overall survival (OS), intrahepatic progression-free survival (InPFS), and adverse events were evaluated.
Symptomatic hepatic arterioportal fistula-related portal vein hypertension.
J Vasc Surg Venous Lymphat Disord
January 2025
Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China. Electronic address:
Intrahepatic Arterioportal Fistula With Subsequent Portal Hypertension After Percutaneous Liver Biopsy.
ACG Case Rep J
March 2024
Department of Gastroenterology, Transplant Hepatology, Westchester Medical Center, Valhalla, NY.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!